Prevalence of Neurofibromatosis in the Philippines
Neurofibromatosis type 1 (NF1) affects approximately 1 in 3,000 individuals worldwide, making it one of the most common genetic disorders globally, though specific prevalence data for the Philippines is not available. 1, 2
Epidemiology of Neurofibromatosis
- NF1 is the most common type of neurofibromatosis, affecting 1 in 2,000-3,000 people worldwide, with no known variation in prevalence specific to the Philippines 1, 2
- NF2 is much rarer, affecting approximately 1 in 25,000-33,000 individuals globally 3, 4
- Both conditions are autosomal dominant disorders, with about 50% of cases being new mutations (sporadic cases) and 50% being inherited from an affected parent 5
- There is no documented ethnic or geographical variation in NF1 prevalence that would suggest a different rate in the Philippines compared to global statistics 2
Types of Neurofibromatosis
Neurofibromatosis Type 1 (NF1)
- Caused by mutations in the NF1 gene on chromosome 17, which encodes neurofibromin, a negative regulator of the RAS-MAPK pathway 4
- Characterized by café-au-lait macules, neurofibromas, intertriginous freckling, and Lisch nodules 6
- Optic pathway gliomas occur in 15-20% of NF1 patients, typically in young children 1
- Plexiform neurofibromas are often congenital but grow during the first two decades of life 4
Neurofibromatosis Type 2 (NF2)
- Caused by mutations in the NF2 gene on chromosome 22, which encodes merlin (schwannomin) 4
- Defined by bilateral vestibular schwannomas on the eighth cranial nerves 4, 3
- Multiple meningiomas and other central nervous system tumors are common features 4
Clinical Impact and Mortality
- NF1 is associated with an 8-15 year reduction in average life expectancy, primarily due to malignant neoplasms and cardiovascular causes 2
- The risk of malignant peripheral nerve sheath tumors (MPNST) in NF1 patients is 8.5% by age 30,12.3% by age 50, and 15.8% by age 85 2, 7
- High-grade MPNSTs are usually fatal and contribute significantly to NF1 mortality 2, 7
- Chronic pain is a common but underrecognized problem in NF1 patients 8
Diagnostic Approach
- The American College of Medical Genetics and Genomics recommends evaluation by and care coordination with a specialized NF clinic 7
- Diagnosis is primarily clinical, based on established criteria including café-au-lait macules, neurofibromas, and other characteristic findings 6
- Genetic testing can confirm diagnosis in uncertain cases 2
Management Recommendations
- Annual general medical evaluation is recommended, including assessment for signs of MPNST, pheochromocytoma, neuropathy, depression, and chronic pain 7
- Women with NF1 should begin annual mammograms at age 30 and consider breast MRI with contrast between ages 30-50 7
- Baseline MRI of known or suspected non-superficial plexiform neurofibromas should be considered 7
- Pregnant women with NF1 should be referred to a high-risk obstetrician 7
Clinical Pitfalls and Special Considerations
- NF1 is often progressive, with new manifestations appearing over time 6
- The condition shows extreme variability in expression, even within families 6
- NF1 should not be underestimated as a "mere cosmetic problem" due to the increased risk of malignant tumors 5
- Metabolic bone disease is common; many patients are frankly osteopenic, which complicates treatment of orthopedic manifestations 9